<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a randomised, double-blind, 22-week trial 400 patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> associated with neuropsychiatric features were treated with Ginkgo biloba extract EGb 761 (240 mg/day) or placebo </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with probable <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, possible <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> with cerebrovascular disease or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> were eligible if they scored 9 to 23 on the SKT cognitive test battery and at least 5 on the Neuropsychiatric Inventory (NPI) </plain></SENT>
<SENT sid="2" pm="."><plain>EGb 761 was significantly superior to placebo with respect to the primary (SKT test battery) and <z:hpo ids='HP_0000001'>all</z:hpo> secondary outcome variables </plain></SENT>
<SENT sid="3" pm="."><plain>The mean composite score (frequency x severity) and the mean caregiver distress score of the NPI dropped from 21.3 to 14.7 and 13.5 to 8.7, respectively, in the EGb 761-treated patients, but increased from 21.6 to 24.1 and 13.4 to 13.9, respectively, under placebo (p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>The largest drug-placebo differences in favour of EGb 761 were found for <z:hpo ids='HP_0000741'>apathy</z:hpo>/indifference, <z:hpo ids='HP_0000739'>anxiety</z:hpo>, <z:hpo ids='HP_0000737'>irritability</z:hpo>/lability, <z:hpo ids='HP_0000716'>depression</z:hpo>/<z:e sem="disease" ids="C0233477" disease_type="Mental or Behavioral Dysfunction" abbrv="">dysphoria</z:e> and sleep/nighttime behaviour </plain></SENT>
</text></document>